Why the study?
Medical management of VT in cardiac sarcoidosis has high failure rates, and the role of catheter ablation had only been studied in small, single-center cohorts.
Does catheter ablation improve outcomes in patients with cardiac sarcoidosis and ventricular tachycardia?
Population
158 consecutive patients with cardiac sarcoidosis and VT across 16 centers
Comparison
Catheter ablation of CS-associated VT and, as appropriate, medical treatment
Design
Multicenter international registry-based cohort study
Follow-up
Median 2.5 years
Key result
Catheter ablation for VT in cardiac sarcoidosis eliminated VT storm in 82% of patients, though 51% experienced VT recurrence, heart transplant, or death over a median 2.5 years.
Authors
Loading...
Ablation may acutely resolve VT storm in cardiac sarcoidosis; leaves open durable benefit versus medical therapy.
Cohort (n=158)
Yes
Does catheter ablation improve outcomes in patients with cardiac sarcoidosis and ventricular tachycardia?
Catheter ablation for ventricular tachycardia in cardiac sarcoidosis is associated with significant reductions in defibrillator shocks and VT storm, though long-term recurrence remains common, particularly in patients with baseline LV dysfunction or myocardial inflammation.
Siontis et al. (2021) conducted a cohort in Cardiac sarcoidosis with ventricular tachycardia (n=158). Catheter ablation was evaluated on composite of VT recurrence, heart transplant (HT), or death. Catheter ablation for VT in cardiac sarcoidosis eliminated VT storm in 82% of patients, though 51% experienced VT recurrence, heart transplant, or death over a median 2.5 years.